Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease

Nature Reviews Nephrology

Volumn 5, Issue 4, 2009, Pages 221-228

  Ecder, Tevfik ^a   Schrier, Robert W ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; AMLODIPINE; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHEMOREPELLENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; METOPROLOL; N(G),N(G) DIMETHYLARGININE; POLYCYSTIN 1; POLYCYSTIN 2; RAMIPRIL; RENIN; TELMISARTAN; UNCLASSIFIED DRUG; VASOPRESSIN; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL TRIAL; CORONARY FLOW RESERVE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTRACRANIAL ANEURYSM; KIDNEY DYSFUNCTION; KIDNEY POLYCYSTIC DISEASE; MORBIDITY; MORTALITY; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VALVULAR HEART DISEASE; VASOPRESSIN BLOOD LEVEL; BLOOD PRESSURE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 67049114683     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.13     Document Type: Review

References (97)

1. ecder, T. et al. in Diseases of the Kidney and Urinary Tract (ed. Schrier, R. W.) 502-539. (Lippincott williams & wilkins, Philadelphia, 2007).
2. PKD Foundation. Polycystic Kidney Disease: The Most Common Life-Threatening Genetic Disease. (Polycystic Kidney research Foundation, Kansas City, 2000).
3. Fick, G. M. et al. Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 5, 2048-2056 (1995).
4. Perrone, R. D. et al. survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney DiS. 38, 777-784 (2001).
5. Chapman, A. B. & Schrier, R. W. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin. Nephrol. 11, 653-660 (1991).
6. ecder, T. & Schrier, R. W. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspectS. J. Am. Soc. Nephrol. 12, 194-200 (2001).
7. Gabow, P. A. et al. Factors affecting the progression of renal disease in autosomaldominant polycystic kidney disease. Kidney Int. 41, 1311-1319 (1992).
8. Chapman, A. B. et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 8, 1292-1297 (1997).
9. Kelleher, C. L. et al. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am. J. HypertenS. 17, 1029-1034 (2004).
10. Schrier, R. W. et al. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 64, 1792-1799 (2003).
11. sedman, A. et al. Autosomal dominant polycystic kidney disease in childhood: A longitudinal study. Kidney Int. 31, 1000-1005 (1987).
12. Fick, G. M. et al. The spectrum of autosomal dominant polycystic kidney disease in children. J. Am. Soc. Nephrol. 4, 1654-1660 (1994).
13. Ivy, D. D. et al. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 5, 2032-2036 (1995).
14. Shamshirsaz, A. et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int. 68, 2218-2224 (2005).
15. Gabow, P. A. et al. renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 38, 1177-1180 (1990).
16. Graham, P. C. & Lindop, G. B. M. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int. 33, 1084-1090 (1988).
17. Torres, V. E. et al. synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int. 42, 364-373 (1992).
18. Loghman-Adham, M. et al. The intrarenal reninangiotensin system in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 287, F775-F788 (2004).
19. Chapman, A. B. et al. The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1091-1096 (1990).
20. Torres, v. E. et al. effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin. Proc. 66, 1010-1017 (1991).
21. Watson, M. L. et al. effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int. 41, 206-210 (1991).
22. Doulton, T. W. et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J. HypertenS. 24, 939-945 (2006).
23. Harrap, S. B. et al. renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int. 40, 501-508 (1991).
24. Barrett, B. J. et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family memberS. Kidney Int. 46, 1118-1123 (1994).
25. Torres, v. E. et al. Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin. Proc. 64, 509-515 (1989).
26. Klein, i. H. et al. sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J. Am. Soc. Nephrol. 12, 2427-2433 (2001).
27. Bakris, G. et al. role of vasopressin in essential hypertension: racial differenceS. J. HypertenS. 15, 545-550 (1997).
28. Fernandes, S. et al. Chronic v2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 143, 2759-2766 (2002).
29. Torres, v. E. vasopressin antagonists in polycystic kidney disease. Kidney Int. 68, 2405-2418 (2005).
30. Danielsen, H. et al. expansion of extracellular volume in early polycystic kidney disease. Acta Med. Scand. 219, 399-405 (1986).
31. Hocher, B. et al. renal endothelin system in polycystic kidney disease. J. Am. Soc. Nephrol. 9, 1169-1177 (1998). (Pubitemid 28283879)
32. Munemura, C. et al. epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: Possible evidence of heterogeneity in cystogenesiS. Am. J. Kidney DiS. 24, 561-568 (1994).
33. Giusti, R. et al. Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib. Nephrol. 115, 118-121 (1995).
34. Wang, D. et al. endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 11, 1371-1376 (2000).
35. Wang, D. et al. endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney Int. 64, 1381-1388 (2003).
36. Al-Nimri, M. A. et al. endothelium-derived vasoactive mediators in polycystic kidney disease. Kidney Int. 63, 1776-1784 (2003).
37. Merta, M. et al. role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol. ReS. 52, 433-437 (2003).
38. Wang, D. et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 51, 184-191 (2008).
39. Kocaman, O. et al. endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 43, 854-860 (2004).
40. Turkmen, K. et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arterieS. Clin. J. Am. Soc. Nephrol. 3, 986-991 (2008).
41. Borresen, M. L. et al. Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am. J. Nephrol. 27, 240-246 (2007).
42. Griffin, M. D. et al. vascular expression of polycystin. J. Am. Soc. Nephrol. 8, 616-626 (1997).
43. Torres, v. E. et al. vascular expression of polycystin-2. J. Am. Soc. Nephrol. 12, 1-9 (2001).
44. Koren, M. J. et al. relationship of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114, 345-352 (1991).
45. Zeier, M. et al. elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 3, 1451-1457 (1993).
46. Bardaji, A. et al. Cardiac involvement in autosomal dominant polycystic kidney disease: A hypertensive heart disease. Clin. Nephrol. 56, 211-220 (2002).
47. Cadnapaphornchai, M. A. et al. increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int. 74, 1192-1196 (2008).
48. Saggar-Malik, A. et al. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 309, 1617-1618 (1994).
49. Bardaji, A. et al. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 32, 970-975 (1998).
50. Oflaz, H. et al. Biventricular diastolic dysfunction in patients with autosomal dominant polycystic kidney disease. Kidney Int. 68, 2244-2249 (2005).
51. Verdecchia, P. et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81, 528-536 (1990).
52. Li Kam wa, T. C. et al. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 12, 2075-2080 (1997).
53. Valero, F. A. et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 10, 1020-1026 (1999).
54. Martinez-vea, A. et al. exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: A prehypertensive state. Am. J. Kidney DiS. 44, 216-223 (2004).
55. Almeida, E. A. et al. Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 47, 587-592 (2006).
56. Phillips, R. A. et al. relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjectS. J. Clin. Endocrinol. Metab. 83, 4284-4288 (1998).
57. Ohya, Y. et al. Hyperinsulinemia and left ventricular geometry in a work-site population Japan. Hypertension 27, 729-734 (1996).
58. Vareesangthip, K. et al. insulin resistance in adult polycystic kidney disease. Kidney Int. 52, 503-508 (1997).
59. Lumiaho, A. et al. insulin resistance is related left ventricular hypertrophy in patients with polycystic kidney disease type 1. Am. J. Kidney DiS. 41, 1219-1224 (2003).
60. rocchini, A. P. et al. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin ii. Hypertension 15, 861-866 (1990).
61. Lembo, G. et al. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J. Clin. Invest. 90, 24-29 (1992).
62. Gharavi, A. G. et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am. J. Cardiol. 77, 1315-1319 (1996).
63. Estacio, R. O. et al. Deletion polymorphism of the angiotensin-converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellituS. Am. J. HypertenS. 12, 637-643 (1999).
64. Baboolal, K. et al. Association of the angiotensin i converting enzyme gene deletion polymorphism with early onset of esrF in PKD1 adult polycystic kidney disease. Kidney Int. 52, 607-613 (1997).
65. Perez-Oller, L. et al. influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 34, 273-278 (1999).
66. Van Dijk, M. A. et al. The ACe insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 15, 836-839 (2000).
67. Schiavello, T. et al. Angiotensin-converting enzyme activity and the ACe Alu polymorphism in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 16, 2323-2327 (2001).
68. Ecder, T. et al. No effect of angiotensinconverting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 23, 466-470 (2003).
69. Chapman, A. B. et al. intracranial aneurysms in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 327, 916-920 (1992).
70. Ruggieri, P. M. et al. Occult intracranial aneurysms in polycystic kidney disease: screening with Mr angiography. Radiology 191, 33-39 (1994).
71. Graf, S. et al. intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 17, 819-823 (2002).
72. Hadimeri, H. et al. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 9, 837-841 (1998). (Pubitemid 28209093)
73. Kanagasundaram, N. S. et al. Aneurysm of the splenic artery in a patient with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 14, 183-184 (1999).
74. Torra, R. et al. Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 7, 2483-2486 (1996).
75. Belz, M. M. et al. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 38, 770-776 (2001).
76. Belz, M. M. et al. recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 63, 1824-1830 (2003).
77. Schrier, R. W. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology 11, 124-130 (2006).
78. Schrier, R. W. et al. repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: A prospective tenyear follow-up. J. Am. Soc. Nephrol. 15, 1023-1028 (2004).
79. Leier, C. V. et al. Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann. Intern. Med. 100, 683-688 (1984).
80. Hossack, K. F. et al. echocardiographic findings in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 319, 907-912 (1988).
81. Timio, M. et al. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: A 10-year follow-up in a five-generation kindred. Clin. Nephrol. 37, 245-251 (1992).
82. Lumiaho, A. et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am. J. Kidney DiS. 38, 1208-1216 (2001).
83. Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J. Am. Soc. Nephrol. 5, 2037-2047 (1995).
84. Maschio, G. et al. effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 334, 939-945 (1996).
85. Ecder, T. et al. effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 35, 427-432 (2000).
86. Chapman, A. B. et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 5, 1349-1354 (1994).
87. Van Dijk, M. A. et al. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 18, 2314-2320 (2003).
88. Zeltner, R. et al. renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 23, 573-579 (2008).
89. Schrier, R. W. et al. epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 63, 678-685 (2003).
90. Ecder, T. et al. Progress in the blood pressure control in autosomal dominant polycystic kidney disease. Am. J. Kidney DiS. 36, 266-271 (2000).
91. ecder, T. et al. Diuretics versus angiotensinconverting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 21, 98-103 (2001).
92. Nutahara, K. et al. Calcium channel blocker versus angiotensin ii receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin. Pract. 99, c18-c23 (2005).
93. Jafar, T. H. et al. The effect of angiotensinconverting enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 67, 265-271 (2005).
94. Ecder, T. et al. reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 14, 1113-1116 (1999).
95. Schrier, R. et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J. Am. Soc. Nephrol. 13, 1733-1739 (2002).
96. Chapman, A. B. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CrisP and HALT-PKD studies. Clin. J. Am. Soc. Nephrol. 3, 1197-1204 (2008).
97. Schrier, R. W. renal volume, renin- angiotensin-aldosterone system, hypertension and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. (in press).